Evinacumab vs SHR-1918
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Homozygous Familial Hypercholesterolemia
Shared mechanism: ANGPTL3 · full Homozygous Familial Hypercholesterolemia pipeline
Evinacumab · Evkeeza
Marketed by Regeneron Pharmaceuticals and partners
NCT03399786 · Phase 3 · completed
The trial randomized 65 participants to evinacumab or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary LDL-C endpoint was statistically significantly improved with evinacumab, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure.
Reported efficacy
Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand): Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) (Week 24): Evinacumab 15 mg/kg IV Q4W -47.1% (Standard Error 4.6) vs Placebo IV Q4W 1.9% (Standard Error 6.5) (met)
Result source: NCT03399786
SHR-1918
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06723652 · Phase 3 · completed
This is a randomized, quadruple-blinded, placebo-controlled trial with a disease-defining efficacy endpoint (percent change in LDL cholesterol), but results have not been posted, so whether SHR-1918 lowered LDL cholesterol significantly versus placebo cannot yet be confirmed from this record.
Reported efficacy
Percent change in calculated LDL-C from baseline to week 12: LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026 (met)
Result source: NCT06723652
Results for Homozygous Familial Hypercholesterolemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Evinacumab
show 6 more results
show 6 more results
show 6 more results
show 5 more results
Available safety results
Evinacumab
| Dropout rate | 0%15 mg/kg NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 show 8 more results—15 mg/kg NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%15 mg/kg IV NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%15 mg/kg IV Q4W NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 — NCT03409744 · Phase 3 · monotherapy |
|---|---|
| Discontinued due to AEs | —15 mg/kg NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 show 8 more results—15 mg/kg NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg/kg IV NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg/kg IV Q4W NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 — NCT03409744 · Phase 3 · monotherapy |
| Serious AEs | 4.5%15 mg/kg NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 show 8 more results15.9%15 mg/kg NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg/kg IV NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 7.1%15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 7.1%15 mg NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —15 mg/kg IV Q4W NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 23.3% NCT03409744 · Phase 3 · monotherapy |
| Most frequent reported AEs | 15 mg/kg nasopharyngitis 15.9% (placebo 23.8%) influenza like illness 11.4% (placebo 0%) headache 9.1% (placebo 23.8%) NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 show 6 more results15 mg/kg headache 11.4% (placebo 23.8%) nasopharyngitis 11.4% (placebo 23.8%) back pain 6.8% (placebo 0%) NCT03399786 · Phase 3 · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 15 mg cough 33.3% oropharyngeal pain 33.3% rhinitis allergic 33.3% NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 15 mg covid-19 66.7% cough 33.3% pyrexia 33.3% NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 15 mg oropharyngeal pain 21.4% abdominal pain upper 14.3% diarrhoea 14.3% NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 15 mg covid-19 71.4% headache 28.6% oropharyngeal pain 28.6% NCT04233918 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evinacumab's landscape · SHR-1918's landscape